splenic hemangiosarcoma. BMC Vet Res 11:131.
226 Garrett, L.D., D.H. Thamm, R. Chun, et al. 2002. Evaluation of a 6‐month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16:704–709.
227 Gasch, E.G., P. Rivier, and J.F. Bardet. 2013. Free proximal cortical ulnar autograft for the treatment of distal radial osteosarcoma in a dog. Can Vet J 54:162–166.
228 Gately, S. and R. Kerbel. 2001. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7:427–436.
229 Gavazza, A., G. Lubas, A. Fridman, et al. 2013. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B‐cell lymphoma. Hum Gene Ther 24:728–738.
230 Geigy, C., B. Riond, C.R. Bley, et al. 2013. Multiple myeloma in a dog with multiple concurrent infectious diseases and persistent polyclonal gammopathy. Vet Clin Pathol 42:47–54.
231 Gemignani, F, P.D. Mayhew, M.A. Giuffrida, et al. 2018. Association of surgical approach with complication rate, progression‐free survival time, and disease‐specific survival time in cats with mammary adenocarcinoma: 107 cases (1991–2014). J Am Vet Med Assoc 252(11):1393–1402.
232 Gentilini, F., C. Calzolari, A. Buonacucina, et al. 2005. Different biological behaviour of Waldenstrom Macroglobulinemia in two dogs. Vet Comp Oncol 3:87–97.
233 Gerritsen, R.J., E. Teske, J.S. Kraus, et al. 1998. Multi‐agent chemotherapy for mast cell tumours in the dog. Vet Q 20:28–31.
234 Gieger, T.L. and M.W. Nolan. 2018. Linac‐based stereotactic radiation therapy for canine non‐lymphomatous nasal tumours: 29 cases (2013–2016). Vet Comp Oncol. 16(1):E68–E75
235 Gieger, T., K. Rassnick, S. Siegel, et al. 2008. Palliation of clinical signs in 48 dogs with nasal carcinomas treated with coarse‐fraction radiation therapy. J Am Anim Hosp Assoc 44:116–123.
236 Gieger, T., S. Siegel, K. Rosen, et al. 2013. Reirradiation of canine nasal carcinomas treated with coarsely fractionated radiation protocols: 37 cases. J Am Anim Hosp Assoc 49:318–324.
237 Gillem, J., M. Giuffrida, and E. Krick. 2017. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000–2013). Vet Comp Oncol. 15(2):400–410
238 Gillick, A. and M. Spiegle. 1987. Decarbazine treatment of malignant melanoma in a dog. Can Vet J 28:204.
239 Glasser, S.A., S. Charney, N.G. Dervisis, et al. 2014. Use of an image‐guided robotic radiosurgery system for the treatment of canine nonlymphomatous nasal tumors. J Am Anim Hosp Assoc 50:96–104.
240 Goldschmidt, M.H. and C. Zoltowski. 1981. Anal sac gland adenocarcinoma in the dog: 14 cases. J Small Anim Pract 22:119–128.
241 Goldstein, R.E., C. Long, N.C. Swift, et al. 2001. Percutaneous ethanol injection for treatment of unilateral hyperplastic thyroid nodules in cats. J Am Vet Med Assoc 218:1298–1302.
242 Gores, B.R., J. Berg, J.L. Carpenter, et al. 1994. Surgical treatment of thymoma in cats: 12 cases (1987–1992). J Am Vet Med Assoc 204:1782–1785.
243 Gower, K.L., J.M. Liptak, W.T. Culp, et al. 2015. Splenic liposarcoma in dogs: 13 cases (2002–2012). J Am Vet Med Assoc 247:1404–1407.
244 Granov, A.M., A.V. Pavlovskii, D.A. Granov, et al. 2005. Radiopaque oil chemical arterial embolization in treatment of pancreatic cancer. Vestn Ross Akad Med Nauk 8: 16–21.
245 Grant, I.A., C.O. Rodriguez, M.S. Kent, et al. 2008. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 22:388–393.
246 Graves, G.M., D.E. Bjorling, and E. Mahaffey. 1988. Canine hemangiopericytoma: 23 cases (1967–1984). J Am Vet Med Assoc 192:99–102.
247 Green, E.M., W.M. Adams, and L.J. Forrest. 2002. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 38:445–451.
248 Green, M.L., J.D. Smith, and P.H. Kass. 2011. Surgical versus non‐surgical treatment of feline small intestinal adenocarcinoma and the influence of metastasis on long‐term survival in 18 cats (2000–2007). Can Vet J 52:1101–1105.
249 Greene, S.N. and R.M. Bright. 2008. Insulinoma in a cat. J Small Anim Pract 49:38–40.
250 Greene, S.N., M.D. Lucroy, C.B. Greenberg, et al. 2007. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 231:1056–1060.
251 Greenlee, P.G., D.A. Filippa, F.W. Quimby, et al. 1990. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 66:480–490.
252 Griessmayr, P.C., M. Gauthier, L.G. Barber, et al. 2007. Mushroom‐derived maitake Petfraction as single agent for the treatment of lymphoma in dogs. J Vet Intern Med 21:1409–1412.
253 Griessmayr, P.C., S.E. Payne, J.E. Winter, et al. 2009. Dacarbazine as single‐agent therapy for relapsed lymphoma in dogs. J Vet Intern Med 23:1227–1231.
254 Griffin, A.M., C.I. Dickie, C.N. Catton, et al. 2015. The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications in extremity soft tissue sarcoma. Ann Surg Oncol 22:2824–2830.
255 Grosenbaugh, D.A., A.T. Leard, P.J. Bergman, et al. 2011. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72:1631–1638.
256 Gualtieri, M., M.G. Monzeglio, and M. Di Giancamillo. 1999a. Oesophageal squamous cell carcinoma in two cats. J Small Anim Pract 40:79–83.
257 Gualtieri, M., M.G. Monzeglio, and E. Scanziani. 1999b. Gastric neoplasia. Vet Clin North Am Small Anim Pract 29:415–440.
258 Guerin, V.J., K.W. Thooft, H.F. L’Eplattenier, et al. 2012. Transitional cell carcinoma involving the ductus deferens in a dog. J Am Vet Med Assoc 240:446–449.
259 Guo, Y., C. Shu, X. Zhou, et al. 2012. High‐dose preoperative fractionated radiotherapy does not affect the patency and healing of eptfe vascular prosthesis after replacement of canine abdominal aorta and inferior vena cava. Eur J Vasc Endovasc Surg 43:460–465.
260 Gustafson, N.R., S.E. Lana, M.N. Mayer, et al. 2004. A preliminary assessment of whole‐body radiotherapy interposed within a chemotherapy protocol for canine lymphoma. Vet Comp Oncol 2:125–131.
261 Gyorffy, S., J.C. Rodriguez‐Lecompte, J.P. Woods, et al. 2005. Bone marrow‐derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 19:56–63.
262 Hafeman, S., C. London, R. Elmslie, et al. 2010. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother 59:441–452.
263 Hafeman, S.D., D. Varland, and S.W. Dow. 2012. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol 10:44–56.
264 Hahn, N.M., P.L. Bonney, D. Dhawan, et al. 2012. Subcutaneous 5‐azacitidine treatment of naturally occurring canine urothelial carcinoma: A novel epigenetic approach to human urothelial carcinoma drug development. J Urol 187:302–309.
265 Hahn, K.A., L. Bravo, W.H. Adams, et al. 1994. Naturally occurring tumors in dogs as comparative models for cancer therapy research. in vivo 8:133–143.
266 Hahn, K.A., G.K. King, and J.K. Carreras. 2004. Efficacy of radiation therapy for incompletely resected grade‐Iii mast cell tumors in dogs: 31 cases (1987–1998). J Am Vet Med Assoc 224:79–82.
267 Hahn, K.A., D.W. Knapp, R.C. Richardson, et al. 1992. Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs. J Am Vet Med Assoc 200:355–357.
268 Hahn, K.A., A.M. Legendre, N.G. Shaw, et al. 2010. Evaluation of 12‐ and 24‐month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res 71:1354–1361.
269 Hahn,